Dogwood Therapeutics, Inc. Common Stock (DWTX)

• Market cap: $10.3M
• 1 day: -27.76%
• 5 days: 75.28%
• 1 month: 15.20%
• 3 months: 227.54%
• 6 months: 3,866.14%
• Year to date: 207.97%
• 1 year: 2,361.78%
• 5 years: -53.74%
• 10 years: -53.74%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 4

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1.52% less ownership

Funds ownership: 3.83% [Q3] → 2.31% (-1.52%) [Q4]

58% less capital invested

Capital invested by funds: $180K [Q3] → $76.5K (-$104K) [Q4]

58% less funds holding

Funds holding: 24 [Q3] → 10 (-14) [Q4]

93% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 14

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 9